Tailored Medical Management of the Complex Postoperative Crohn's Disease Patient

Abstract

Despite advancements in medical therapy, many patients with Crohn's disease continue to require surgery for intestinal resection and/or management of perianal disease at some point in their disease course. Unfortunately, in this complex group of patients, postoperative disease recurrence rates are high. Medical prophylaxis can be used to prevent Crohn's disease recurrence or manage residual disease after surgery, but the ideal timing to start medications after surgery varies based on patient risk factors and patient preference for medication use. Currently, the largest medical treatment effects are seen with thiopurines and antitumor necrosis factor antibodies, but there are continually expanding options as new medical therapies are developed. A proposed algorithm stratified based on patient risk factors is provided.

Keywords

Crohn's disease - postoperative recurrence - thiopurines - antitumor necrosis factor antibodies

• References

• 1 De Cruz P, Kamm MA, Prideaux L, Allen PB, Desmond PV. Postoperative recurrent luminal Crohn's disease: a systematic review. Inflamm Bowel Dis 2012; 18 (04) 758-777
• 2 Frolkis AD, Dykeman J, Negrón ME. , et al. Risk of surgery for inflammatory bowel diseases has decreased over time: a systematic review and meta-analysis of population-based studies. Gastroenterology 2013; 145 (05) 996-1006
• 3 Bouguen G, Peyrin-Biroulet L. Surgery for adult Crohn's disease: what is the actual risk?. Gut 2011; 60 (09) 1178-1181
• 4 Splawski JB, Pffefferkorn MD, Schaefer ME. , et al. NASPGHAN clinical report on postoperative recurrence in pediatric Crohn disease. J Pediatr Gastroenterol Nutr 2017; 65 (04) 475-486
• 5 Frolkis AD, Lipton DS, Fiest KM. , et al. Cumulative incidence of second intestinal resection in Crohn's disease: a systematic review and meta-analysis of population-based studies. Am J Gastroenterol 2014; 109 (11) 1739-1748
• 6 Ahmed T, Rieder F, Fiocchi C, Achkar JP. Pathogenesis of postoperative recurrence in Crohn's disease. Gut 2011; 60 (04) 553-562
• 7 McLeod RS, Wolff BG, Ross S, Parkes R, McKenzie M. ; Investigators of the CAST Trial. Recurrence of Crohn's disease after ileocolic resection is not affected by anastomotic type: results of a multicenter, randomized, controlled trial. Dis Colon Rectum 2009; 52 (05) 919-927
• 8 Strong S, Steele SR, Boutrous M. , et al; Clinical Practice Guidelines Committee of the American Society of Colon and Rectal Surgeons. Clinical practice guideline for the surgical management of Crohn's disease. Dis Colon Rectum 2015; 58 (11) 1021-1036
• 9 Simillis C, Jacovides M, Reese GE, Yamamoto T, Tekkis PP. Meta-analysis of the role of granulomas in the recurrence of Crohn disease. Dis Colon Rectum 2010; 53 (02) 177-185
• 10 Lemmens B, de Buck van Overstraeten A, Arijs I. , et al. Submucosal plexitis as a predictive factor for postoperative endoscopic recurrence in patients with Crohn's disease undergoing a resection with ileocolonic anastomosis: results from a prospective single-centre study. J Crohn's Colitis 2017; 11 (02) 212-220
• 11 Li Y, Stocchi L, Liu X. , et al. Presence of granulomas in mesenteric lymph nodes is associated with postoperative recurrence in Crohn's disease. Inflamm Bowel Dis 2015; 21 (11) 2613-2618
• 12 Reese GE, Nanidis T, Borysiewicz C, Yamamoto T, Orchard T, Tekkis PP. The effect of smoking after surgery for Crohn's disease: a meta-analysis of observational studies. Int J Colorectal Dis 2008; 23 (12) 1213-1221
• 13 Gionchetti P, Dignass A, Danese S. , et al; ECCO. 3rd European evidence-based consensus on the diagnosis and management of Crohn's disease 2016: Part 2: Surgical management and special situations. J Crohn's Colitis 2017; 11 (02) 135-149
• 14 Rutgeerts P, Goboes K, Peeters M. , et al. Effect of faecal stream diversion on recurrence of Crohn's disease in the neoterminal ileum. Lancet 1991; 338 (8770): 771-774
• 15 Cosnes J, Beaugerie L, Carbonnel F, Gendre JP. Smoking cessation and the course of Crohn's disease: an intervention study. Gastroenterology 2001; 120 (05) 1093-1099
• 16 Ryan WR, Allan RN, Yamamoto T, Keighley MR. Crohn's disease patients who quit smoking have a reduced risk of reoperation for recurrence. Am J Surg 2004; 187 (02) 219-225
• 17 Olaison G, Smedh K, Sjödahl R. Natural course of Crohn's disease after ileocolic resection: endoscopically visualised ileal ulcers preceding symptoms. Gut 1992; 33 (03) 331-335
• 18 Rutgeerts P, Geboes K, Vantrappen G, Kerremans R, Coenegrachts JL, Coremans G. Natural history of recurrent Crohn's disease at the ileocolonic anastomosis after curative surgery. Gut 1984; 25 (06) 665-672
• 19 Onali S, Calabrese E, Petruzziello C. , et al. Post-operative recurrence of Crohn's disease: a prospective study at 5 years. Dig Liver Dis 2016; 48 (05) 489-494
• 20 Rutgeerts P, Geboes K, Vantrappen G, Beyls J, Kerremans R, Hiele M. Predictability of the postoperative course of Crohn's disease. Gastroenterology 1990; 99 (04) 956-963
• 21 Nguyen GC, Loftus Jr EV, Hirano I, Falck-Ytter Y, Singh S, Sultan S. ; AGA Institute Clinical Guidelines Committee. American gastroenterological association institute guideline on the management of Crohn's disease after surgical resection. Gastroenterology 2017; 152 (01) 271-275
• 22 De Cruz P, Kamm MA, Hamilton AL. , et al. Crohn's disease management after intestinal resection: a randomised trial. Lancet 2015; 385 (9976): 1406-1417
• 23 Regueiro M, Velayos F, Greer JB. , et al. American gastroenterological association institute technical review on the management of Crohn's disease after surgical resection. Gastroenterology 2017; 152 (01) 277-295.e3
• 24 Gordon M, Taylor K, Akobeng AK, Thomas AG. Azathioprine and 6-mercaptopurine for maintenance of surgically-induced remission in Crohn's disease. Cochrane Database Syst Rev 2014; (08) CD010233
• 25 Mowat C, Arnott I, Cahill A. , et al; TOPPIC Study Group. Mercaptopurine versus placebo to prevent recurrence of Crohn's disease after surgical resection (TOPPIC): a multicentre, double-blind, randomised controlled trial. Lancet Gastroenterol Hepatol 2016; 1 (04) 273-282
• 26 Regueiro M, Schraut W, Baidoo L. , et al. Infliximab prevents Crohn's disease recurrence after ileal resection. Gastroenterology 2009; 136 (02) 441-50.e1 , quiz 716
• 27 Yoshida K, Fukunaga K, Ikeuchi H. , et al. Scheduled infliximab monotherapy to prevent recurrence of Crohn's disease following ileocolic or ileal resection: a 3-year prospective randomized open trial. Inflamm Bowel Dis 2012; 18 (09) 1617-1623
• 28 Sorrentino D, Terrosu G, Paviotti A. , et al. Early diagnosis and treatment of postoperative endoscopic recurrence of Crohn's disease: partial benefit by infliximab--a pilot study. Dig Dis Sci 2012; 57 (05) 1341-1348
• 29 Papamichael K, Archavlis E, Lariou C, Mantzaris GJ. Adalimumab for the prevention and/or treatment of post-operative recurrence of Crohn's disease: a prospective, two-year, single center, pilot study. J Crohn's Colitis 2012; 6 (09) 924-931
• 30 Savarino E, Bodini G, Dulbecco P. , et al. Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease: a randomized controlled trial. Am J Gastroenterol 2013; 108 (11) 1731-1742
• 31 Regueiro M, Feagan BG, Zou B. , et al; PREVENT Study Group. Infliximab reduces endoscopic, but not clinical, recurrence of Crohn's disease after ileocolonic resection. Gastroenterology 2016; 150 (07) 1568-1578
• 32 Singh S, Garg SK, Pardi DS, Wang Z, Murad MH, Loftus Jr EV. Comparative efficacy of pharmacologic interventions in preventing relapse of Crohn's disease after surgery: a systematic review and network meta-analysis. Gastroenterology 2015; 148 (01) 64-76.e2 , quiz e14